These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9279888)

  • 21. Plasmin inhibitors in the prevention of systemic effects during thrombolytic therapy: specific role of the plasminogen-binding form of alpha 2-antiplasmin.
    Leebeek FW; Kluft C; Knot EA; Los P; Cohen AF; Six AJ
    J Am Coll Cardiol; 1990 May; 15(6):1212-20. PubMed ID: 1691750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-thrombolysis haemostasis changes after rt-PA treatment in acute cerebral infarct. Correlations with cardioembolic aetiology and outcome.
    Sun X; Berthiller J; Derex L; Trouillas P; Diallo L; Hanss M
    J Neurol Sci; 2015 Feb; 349(1-2):77-83. PubMed ID: 25619569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolonged systemic delivery of streptokinase using liposome.
    Kim IS; Choi HG; Choi HS; Kim BK; Kim CK
    Arch Pharm Res; 1998 Jun; 21(3):248-52. PubMed ID: 9875439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolonged activation of fibrinolytic system induced by fibrin nonselective thrombolytic agent can contribute to preventing early reocclusion after coronary thrombolytic therapy.
    Goto S; Kawai Y; Handa S; Takahashi E; Ogawa S; Watanabe K; Hori S; Ikeda Y
    Cardiology; 1993; 82(4):274-9. PubMed ID: 8402754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.
    Monassier JP; Hanssen M
    Drugs; 1987; 33 Suppl 3():247-52. PubMed ID: 2445540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A proposed reference method for plasminogen activators that enables calculation of enzyme activities in SI units.
    Longstaff C; Whitton CM
    J Thromb Haemost; 2004 Aug; 2(8):1416-21. PubMed ID: 15304049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Thrombolytics and their use].
    Alessi MC; Juhan-Vague I
    Rev Prat; 1999 Oct; 49(15):1654-8. PubMed ID: 10581996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasminogen activators: a comparison.
    Baruah DB; Dash RN; Chaudhari MR; Kadam SS
    Vascul Pharmacol; 2006 Jan; 44(1):1-9. PubMed ID: 16275118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Staphylokinase--a specific plasminogen activator].
    Rozpończyk E; Szemraj J; Malinowski M; Rozpończyk J
    Postepy Biochem; 2006; 52(1):80-6. PubMed ID: 16869305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulation savers: thrombolytic therapy.
    Felicilda-Reynaldo RF
    Medsurg Nurs; 2013; 22(6):393-7. PubMed ID: 24600937
    [No Abstract]   [Full Text] [Related]  

  • 31. Dose-ranging studies of anisoylated plasminogen streptokinase activator complex. Studies in healthy volunteers and in patients with acute myocardial infarction.
    Marder VJ; Rothbard RL; Fitzpatrick PG; Francis CW; Norry EC
    Drugs; 1987; 33 Suppl 3():124-32. PubMed ID: 3315577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Blood coagulation mechanism from the viewpoint of molecular biochemistry: Mechanism of fibrinolysis].
    Matsuda T
    Rinsho Byori; 1985 Sep; 33(9):982-8. PubMed ID: 2416968
    [No Abstract]   [Full Text] [Related]  

  • 34. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture.
    Collen D
    Thromb Haemost; 1980 Jun; 43(2):77-89. PubMed ID: 6450468
    [No Abstract]   [Full Text] [Related]  

  • 35. Severe backache during thrombolytic therapy with streptokinase.
    Suresh V; Maliyil MV
    J Assoc Physicians India; 1996 Oct; 44(10):743. PubMed ID: 9251356
    [No Abstract]   [Full Text] [Related]  

  • 36. Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis.
    Marsh JN; Senpan A; Hu G; Scott MJ; Gaffney PJ; Wickline SA; Lanza GM
    Nanomedicine (Lond); 2007 Aug; 2(4):533-43. PubMed ID: 17716136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibrin clot structure - pro-fibrinolytic effect of oral contraceptives in apparently healthy women.
    Sidelmann JJ; Kluft C; Krug AH; Winkler U; Jespersen J; Gram JB
    Thromb Haemost; 2017 Apr; 117(4):700-705. PubMed ID: 28150855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasmin inhibitors and fibrinogen breakdown during the initial phase of thrombolytic treatment--the problem of the alpha 2-antiplasmin determination.
    Noll G; Lämmle B; Duckert F
    Thromb Haemost; 1984 Jul; 51(3):334-7. PubMed ID: 6238441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasmin inhibitors in different fibrinolytic treatment patterns.
    Lasierra J; Diez M; Perera C; Viladés E
    Haemostasis; 1981; 10(1):51-62. PubMed ID: 6162721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Fibrinolysis: kinetics of the lysis of a fibrin clot].
    Daver J; Edmond E; Panak E; Ricoeur M
    Rev Eur Etud Clin Biol; 1970 Mar; 15(3):333-42. PubMed ID: 4246032
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.